Related Articles
Multicenter phase II study of infusional 5‑fluorouracil (5‑FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first‑line treatment in patients with metastatic colorectal cancer (CELINE trial)
Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer
Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study
Complete response of MSI‑high metastatic colon cancer following treatment with regorafenib: A case report
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin‑ or irinotecan‑based treatment